Ventyx Biosciences
Biotechnology Research • 
12790 El Camino Real, San Diego, United States • 201-500 Employees
Company overview
| Headquarters | 12790 El Camino Real, San Diego, United States |
| Phone number | +18589452393 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Employees | 201-500 |
| Socials |
Key Contacts at Ventyx Biosciences
Fatemeh Akhlaghi
Senior Director, Head Of Clinical Pharmacology
Jason Callahan
Director, Clinical Operations
Joann Tien
Director, Regulatory Operations And Affairs
Valentina Jelicic
Sr Director Qa Ops And Supplier Quality
Runkai Li Anal Dev
Senior Director, Technical Operations Cmc, Head Of Analytical Development And Qc
Henrik H. Sonnergren
Senior Medical Director Clinical Development
Will Steinhauff
Associate Director, Drug Product
Michael Moro
Senior Director, Clinical Supplies
Stacy Macdonald
Senior Director
Bipin Patel
Associate Director, Drug Product Formulation And Manufacturing
Ventyx Biosciences Email Formats
Ventyx Biosciences uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@ventyxbio.com), used 53.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@ventyxbio.com | 53.4% |
{first name}{last name} | johndoe@ventyxbio.com | 34.5% |
{last name}{last name} | doedoe@ventyxbio.com | 6.9% |
{last name}{first initial} | doej@ventyxbio.com | 3.4% |
{first3}{last name} | {first3}doe@ventyxbio.com | 1.7% |
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our deep expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials. Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor, and VTX3232, a CNS-penetrant NLRP3 inhibitor. Our inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.
Ventyx Biosciences revenue & valuation
| Annual revenue | $23,200,000 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $74,200,000 |
| Total funding | $303,600,000 |
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Ventyx Biosciences has 37 employees across 9 departments.
Departments
Number of employees
Funding Data
Explore Ventyx Biosciences's funding history, including investment rounds, total capital raised, and key backers.
United Kingdom
South Africa
Canada
Frequently asked questions
4.8
40,000 users
